Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database
November 2024
in “
Circulation
”
Studysummary This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications. Our plain-language summary of this paper — not a Tressless recommendation.
A real-world pharmacovigilance study using the FAERS database investigated the safety concerns of glucagon-like peptide 1 receptor agonists (GLP1-RAs) related to suicide, hair loss, and aspiration. The study found no positive signals for these adverse events with GLP1-RAs, although they showed higher reporting rates compared to other antidiabetic medications. Specifically, semaglutide and liraglutide had higher suicidal event reports, and GLP1-RAs were the most reported class for hair loss. Despite not meeting the criteria for positive signals, the findings suggest the need for continued monitoring and reporting of these events.
